Chromadex Corp expected to post a loss of 3 cents a share - Earnings Preview

Niagen Bioscience

27/10/2023 12:09

* Chromadex Corp  CDXC.OQ   CDXC.O  is expected to show a
rise in
quarterly revenue when it reports  results 
    * The Los Angeles California-based  company is expected to
report 
a 18.7% increase in revenue to $20.25 million from $17.06
million a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Chromadex Corp is
for a
loss of 3 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Chromadex
Corp is
$5​, above​ its last closing price of $1.32. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.04       -0.04      -0.03     Beat    20
 Mar. 31 2023  -0.05       -0.05      -0.03     Beat    37.5
 Dec. 31 2022  -0.03       -0.02      -0.02     Met     17.3​
 Sep. 30 2022  -0.06       -0.06      -0.04     Beat    35.5
 ​​Jun.        -0.08       -0.08      -0.09     Missed  -5.9
 30 2022                                                
 Mar. 31 2022  -0.09       -0.09      -0.11     Missed  -19.6​
 Dec. 31 2021  -0.11       -0.10      -0.08     Beat    20
 Sep. 30 2021  -0.09       -0.09      -0.13     Missed  -41.3
 This summary was machine generated October 27 at 11:09 GMT.  All
figures in US dollars  unless otherwise stated